Merck & Co., Inc. $MRK Stake Reduced by Barrow Hanley Mewhinney & Strauss LLC

Merck & Co., Inc. logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Barrow Hanley cut its Merck stake by 69.8% in the third quarter, selling 5.12 million shares and retaining about 2.21 million shares valued at $321.7 million.
  • Merck reported quarterly EPS of $2.49, beating estimates of $2.09, while revenue rose 4.7% year over year to $18.09 billion. It also increased its quarterly dividend from $0.85 to $0.88 per share.
  • Analysts’ consensus rating is Moderate Buy, with an average price target of $155.74; one analyst rated the stock Strong Buy, 16 Buy, and 12 Hold.
  • Five stocks we like better than Merck & Co., Inc..

Barrow Hanley Mewhinney & Strauss LLC reduced its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 69.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,213,929 shares of the company's stock after selling 5,117,489 shares during the quarter. Barrow Hanley Mewhinney & Strauss LLC owned about 0.09% of Merck & Co., Inc. worth $321,706,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of MRK. BlackRock Inc. lifted its position in shares of Merck & Co., Inc. by 0.5% in the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company's stock worth $29,169,479,000 after purchasing an additional 1,073,507 shares during the period. State Street Corp grew its holdings in shares of Merck & Co., Inc. by 0.8% during the 3rd quarter. State Street Corp now owns 121,422,392 shares of the company's stock worth $17,745,131,000 after acquiring an additional 1,009,136 shares during the period. Wellington Management Group LLP grew its stake in Merck & Co., Inc. by 2.3% in the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company's stock worth $11,083,033,000 after purchasing an additional 1,934,312 shares during the period. Fisher Asset Management LLC grew its position in shares of Merck & Co., Inc. by 8.3% in the 3rd quarter. Fisher Asset Management LLC now owns 41,699,432 shares of the company's stock worth $6,059,345,000 after buying an additional 3,183,169 shares during the period. Finally, Bank of America Corp DE grew its position in shares of Merck & Co., Inc. by 10.5% in the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company's stock worth $3,701,831,000 after buying an additional 2,919,780 shares during the period. Hedge funds and other institutional investors own 76.07% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Berenberg Bank upped their price target on Merck & Co., Inc. from $127.00 to $137.00 and gave the company a "hold" rating in a report on Friday, September 11th. Argus started coverage on shares of Merck & Co., Inc. in a research note on Tuesday, November 3rd. They set a "strong-buy" rating on the stock. UBS Group raised their price target on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a "buy" rating in a report on Thursday, August 20th. Daiwa Securities Group upgraded shares of Merck & Co., Inc. from a "neutral" rating to an "outperform" rating and set a $143.00 price target for the company in a research note on Wednesday, August 12th. Finally, Wells Fargo & Company boosted their price objective on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the company an "overweight" rating in a report on Friday, September 4th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $155.74.

View Our Latest Research Report on Merck & Co., Inc.

Merck & Co., Inc. Trading Up 0.6%

Shares of MRK stock opened at $133.56 on Friday. The company has a market cap of $329.26 billion, a PE ratio of 137.69, a price-to-earnings-growth ratio of 6.62 and a beta of 0.13. The stock's 50 day simple moving average is $145.28 and its two-hundred day simple moving average is $129.29. Merck & Co., Inc. has a 1 year low of $95.36 and a 1 year high of $156.92. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.35 and a quick ratio of 1.14.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The firm had revenue of $18.09 billion during the quarter, compared to analyst estimates of $17.33 billion. During the same period last year, the company earned $2.58 EPS. Merck & Co., Inc.'s quarterly revenue was up 4.7% compared to the same quarter last year. Research analysts predict that Merck & Co., Inc. will post 2.82 earnings per share for the current year.

Merck & Co., Inc. Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 8th. Investors of record on Tuesday, December 15th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Tuesday, December 15th. This is an increase from Merck & Co., Inc.'s previous quarterly dividend of $0.85. Merck & Co., Inc.'s payout ratio is 350.52%.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP Richard Deluca sold 58,185 shares of the firm's stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $148.01, for a total transaction of $8,611,961.85. Following the completion of the transaction, the executive vice president directly owned 112,955 shares of the company's stock, valued at approximately $16,718,469.55. This trade represents a 34.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.17% of the company's stock.

Key Merck & Co., Inc. News

Investors following MRK have been watching these news items:

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company's research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Merck & Co., Inc. Right Now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines